

Nicola
GEBBIA

Russo A, Calò V, Agnese V, Bruno L, Corsale S, Augello C, Gargano G, Barbera F, Cascio S, Intrivici C, Rinaldi G, Gulotta G, Macaluso M, Surmacz E, Giordano A, Gebbia N, Bazan V. BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.

Breast Cancer Res Treat. 2007 Nov;105(3):267-76.

Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC. Targeting human $\{\gamma\}\delta$ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Cancer Res. 2007 Aug 1;67(15):7450-7.

Manna G, Foddai E, Di Maggio MG, Pace F, Colucci G, Gebbia N, Russo A. Emotional expression and coping style in female breast cancer.

Ann Oncol. 2007 Jun;18 Suppl 6:vi77-80.

Russo A, Calò V, Augello C, Bruno L, Agnese V, Schirò V, Barbera F, Cascio S, Foddai E, Badalamenti G, Intrivici C, Cajozzo M, Gulotta G, Surmacz E, Colucci G, Gebbia N, Bazan V. 4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

Ann Oncol. 2007 Jun;18 Suppl 6:vi99-102.

Badalamenti G, Rodolico V, Fulfaro F, Cascio S, Cipolla C, Cicero G, Incorvaia L, Sanfilippo M, Intrivici C, Sandonato L, Pantuso G, Latteri MA, Gebbia N, Russo A. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features.

Ann Oncol. 2007 Jun;18 Suppl 6:vi136-40.

Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, Badalamenti G, Russo A, Gebbia N. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): current dental management designs and issues in diagnosis.

Ann Oncol. 2007 Jun;18 Suppl 6:vi168-72.

Agnese V, Cabibi D, Calcara D, Terrasi M, Pantuso G, Fiorentino E, Intrivici C, Colucci G, Aragona F, Gebbia N, Bazan V, Russo A. Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus.

Ann Oncol. 2007 Jun;18 Suppl 6:vi110-5.

Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, DiTrapani D, Gebbia N, Leto G. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.

Anticancer Res. 2007 May-Jun;27(3B):1519-25.

Cipolla C, Fulfaro F, Sandonato L, Fricano S, Pantuso G, Grassi N, Vieni S, Valerio MR, Lo Dico R, Gebbia N, Latteri MA. Clinical presentation and treatment of gastrointestinal stromal tumors.

Tumori. 2006 Jul-Aug;92(4):279-84.

Cicero G, Fulfaro F, Caraceni A, Arcara C, Badalamenti G, Intrivici C, Gebbia N. A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy.

J Chemother. 2006 Jul;18(3):325-7.

Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

Clin Exp Metastasis. 2006;23(2):117-22. Epub 2006 Jul 14.

Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N, Fulfaro F. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.

Ann Oncol. 2006 Jun;17(suppl_7):vii68-vii72.

Simoni D, Roberti M, Invidiata FP, Aiello E, Aiello S, Marchetti P, Baruchello R, Eleopra M, Di Cristina A, Grimaudo S, Gebbia N, Crosta L, Dieli F, Tolomeo M. Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3245-8. Epub 2006 Mar 31.

Lopez M, Comandone A, Adamo V, Apice G, Bearzi I, Bracci R, Carlini M, Carpano S, Condorelli S, Covello R, Cucchiara G, Di Filippo F, Doglietto GB, Ficorella C, Garofalo A, Gebbia N, Giuliani F, Massidda B, Messerini L, Palmirota R, Tonelli F, Vidiri A. [Clinical guidelines for the management of gastrointestinal stromal tumors]

Clin Ter. 2006 May-Jun;157(3):283-99.

Arcara C, Fulfaro F, Badalamenti G, Gebbia N, Arcara M. A case of squamocellular uterine cervix carcinoma metastatic to the skin with heterocutaneous fistula.

Tumori. 2006 May-Jun;92(3):264-6.

Roberti M, Pizzirani D, Recanatini M, Simoni D, Grimaudo S, Di Cristina A, Abbadessa V, Gebbia N, Tolomeo M. Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.

J Med Chem. 2006 May 18;49(10):3012-8.

Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O'Donoghue DP, Agnese V, Cascio S, Di Fede G, Chiecobianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lothe RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capellá GM, Moreno V, Peinado MA, Lönnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh LL, Tang R, Smith DR, Allen-Mersh TG, Khan ZA, Shorthouse AJ, Silverman ML, Kato S, Ishioka C; TP53-CRC Collaborative Group. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

Ann Oncol. 2006 May;17(5):842-7.

Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

Ann Oncol. 2006 May;17(5):835-41.

Calò V, Agnese V, Gargano G, Corsale S, Gregorio V, Cascio S, Cammareri P, Bruno L, Augello C, Gullo A, Sisto PS, Badalamenti G, Valerio MR, Napoli L, Gebbia N, Bazan V, Russo A. A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.

Breast Cancer Res Treat. 2006 Mar;96(1):97-100.

Leto G, Badalamenti G, Arcara C, Crescimanno M, Flandina C, Tumminello FM, Incorvaia L, Gebbia N, Fulfaro F. Effects of zoledronic acid on proteinase plasma levels in patients with bonemetastases.

Anticancer Res. 2006 Jan-Feb;26(1A):23-6.

Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85.

Russo A, Corsale S, Agnese V, Macaluso M, Cascio S, Bruno L, Surmacz E, Dardanoni G, Valerio MR, Vieni S, Restivo S, Fulfaro F, Tomasino RM, Gebbia N, Bazan V. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.

J Cell Physiol. 2006 Jan;206(1):181-8.

Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, Vinciarelli G, Gebbia N, Colucci G; Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).

Am J Clin Oncol. 2005 Dec;28(6):581-5.

Correale P, Fulfaro F, Marsili S, Cicero G, Bajardi E, Intrivici C, Vuolo G, Carli AF, Caraglia M, Del Prete S, Greco E, Gebbia N, Francini G. Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.

Cancer Chemother Pharmacol. 2005 Dec;56(6):563-8. Epub 2005 Jul 23.

Leto G, Incorvaia L, Badalamenti G, Arcara C, Fulfaro F, Tumminello FM, Flandina C, Crescimanno M, Gebbia N. Tumor markers in urogynaecological tumors.

Tunis Med. 2005 Dec;83 Suppl 12:28.

Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR, Di Fede G, Russo A, Vitale A, Rini GB, Casuccio A, Intrivici C, Gebbia N. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.

J Chemother. 2005 Oct;17(5):555-9.

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.

J Clin Oncol. 2005 Oct 20;23(30):7518-28.

De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello GP, De Vita F, Ficorella C, Farris A, Pistillucci G, Gemini M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco AR. Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.

Br J Cancer. 2005 Oct 17;93(8):896-904.

Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrà F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, Angelini V, Rossi A, Bilancia D, Germano D, Lamberti A, Pontillo V, Brancaccio L, Renda F, Romano F, Esani G, Gambaro A, Vinante O, Azzarello G, Clerici M, Bollina R, Belloni P, Sannicolò M, Ciuffreda L, Parello G, Cabiddu M, Sacco C, Sibau A, Porcile G, Castiglione F, Ostellino O, Monfardini S, Stefani M, Scagliotti G, Selvaggi G, De Marinis F, Martelli O, Gasparini G, Morabito A, Gattuso D, Colucci G, Galetta D, Giotta F, Gebbia V, Borsellino N, Testa A, Malaponte E, Capuano MA, Angiolillo M, Sollitto F, Tirelli U, Spazzapan S, Adamo V, Altavilla G, Scimone A, Hopps MR, Tartamella F, Ianniello GP, Tinessa V, Failla G, Bordonaro R, Gebbia N, Valerio MR, D'Aprile M, Veltri E, Tonato M, Darwish S, Romito S, Carrozza F, Barni S, Ardizzoia A, Corradini GM, Pavia G, Belli M, Colantuoni G, Galligioni E, Caffo O, Labianca R, Quadri A, Cortesi E, D'Auria G, Fava S, Calcagno A, Luporini G, Locatelli MC, Di Costanzo F, Gasperoni S, Isa L, Candido P, Gaion F, Palazzolo G, Nettis G, Annamaria A, Rinaldi M, Lopez M, Felletti R, Di Negro GB, Rossi N, Calandriello A, Maiorino L, Mattioli R, Celano A, Schiavon S, Illiano A, Raucci CA, Caruso M, Foa P, Tonini G, Curcio C, Cazzaniga M. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. *J Clin Oncol.* 2005 Oct 1;23(28):6865-72.

Russo A, Corsale S, Cammareri P, Agnese V, Cascio S, Di Fede G, Macaluso M, Bazan V. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy. *J Cell Physiol.* 2005 Sep;204(3):742-9.

Tolomeo M, Grimaudo S, Di Cristina A, Roberti M, Pizzirani D, Meli M, Dusonchet L, Gebbia N, Abbadessa V, Crosta L, Baruchello R, Grisolia G, Invidiata F, Simoni D. Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. *Int J Biochem Cell Biol.* 2005 Aug;37(8):1709-26. Epub 2005 Apr 26.

Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. *J Clin Oncol.* 2005 Aug 1;23(22):4866-75. Epub 2005 Jun 6.

Simoni D, Giannini G, Roberti M, Rondanin R, Baruchello R, Rossi M, Grisolia G, Invidiata FP, Aiello S, Marino S, Cavallini S, Siniscalchi A, Gebbia N, Crosta L, Grimaudo S, Abbadessa V, Di Cristina A, Tolomeo M. Studies on the apoptotic activity of natural and synthetic retinoids: discovery of a new class of synthetic terphenyls that potently support cell growth and inhibit apoptosis in neuronal and HL-60 cells. *J Med Chem.* 2005 Jun 30;48(13):4293-9.

Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. *Ann Oncol.* 2005 May;16 Suppl 4:iv50-iv55.

Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Borsellino N, Carteni G, Pezzella G, Manzione L, Romito S, Lopez M, Colucci G. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). *Ann Oncol.* 2005 May;16 Suppl 4:iv56-iv60.

Siragusa S, Arcara C, Malato A, Anastasio R, Valerio MR, Fulfarò F, Lo Coco L, Grimaudo S, Bajardi G, Abbadessa V, Gebbia N. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. *Ann Oncol.* 2005 May;16(suppl_4):iv136-iv139.

Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. *Ann Oncol.* 2005 May;16 Suppl 4:iv44-iv49.

Vici P, Foggi P, Colucci G, Capomolla E, Brandi M, Giotta F, Gebbia N, DiLauro L, Valerio MR, Paoletti G, Belli F, Pizza C, Giannarelli D, Lopez M. Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer. *Anticancer Res.* 2005 Mar-Apr;25(2B):1309-14.

Rodolico V, Aragona F, Cabibi D, Di Bernardo C, Di Lorenzo R, Gebbia N, Gulotta G, Leonardi V, Ajello F. Overexpression of cyclin D1 and interaction between p27Kip1 and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell carcinoma. *Oral Oncol.* 2005 Mar;41(3):268-75.

Simoni D, Grisolia G, Giannini G, Roberti M, Rondanin R, Piccagli L, Baruchello R, Rossi M, Romagnoli R, Invidiata FP, Grimaudo S, Jung MK, Hamel E, Gebbia N, Crosta L, Abbadessa V, Di Cristina A, Dusonchet L, Meli M, Tolomeo M. Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. *J Med Chem.* 2005 Feb 10;48(3):723-36.

Bazan V, La Rocca G, Corsale S, Agnese V, Macaluso M, Migliavacca M, Gregorio V, Cascio S, Sisto PS, Di Fede G, Buscemi M, Fiorentino E, Passantino R, Morello V, Tomasino RM, Russo A. Laser pressure catapulting (LPC): optimization LPC-system and genotyping of colorectal carcinomas. *J Cell Physiol.* 2005 Feb;202(2):503-9.

Siragusa S, Anastasio R, Giarratano A, Malato A, Bonifacio G, Arcara C, Gebbia N. Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation. *Exp Oncol.* 2004 Sep;26(3):192-5. Review.

Migliavacca M, Ottini L, Bazan V, Agnese V, Corsale S, Macaluso M, Lupi R, Dardanoni G, Valerio MR, Pantuso G, Di Fede G, Tomasino RM, Gebbia N, Mariani-Costantini R, Russo A. TP53 in gastric cancer: mutations in the I3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.

J Cell Physiol. 2004 Sep;200(3):476-85.

Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N, Schittulli F, Colucci G; Grupo Oncologico Italia Meridionale. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.

Semin Oncol. 2004 Apr;31(2 Suppl 5):13-9.

Leto G, Tumminello FM, Crescimanno M, Flandina C, Gebbia N. Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Clin Exp Metastasis. 2004;21(2):91-106. Review.

Fulfaro F, Valerio MR, Badalamenti G, Gebbia N, Russo A. Antitubercular drug combinations with ifosfamide: an update.

Oncology. 2003;65 Suppl 2:21-30.

Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: from normal control of cellular events to tumorigenesis.

J Cell Physiol. 2003 Nov;197(2):157-68. Review.

Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A. Induction of gamma delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

Blood. 2003 Sep 15;102(6):2310-1. .

Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Piantedosi FV, Cigolari S, Illiano A, Barbera S, Robbiati SF, Piazza E, Ianniello GP, Frontini L, Veltri E, Castiglione F, Rosetti F, De Maio E, Maione P, Gridelli C, Rossi A, Barletta E, Barzelloni ML, Signoriello G, Bilancia D, Dinota A, Rosati G, Germano D, Lamberti A, Pontillo V, Brancaccio L, Crispino C, Esposito M, Battiloro C, Tufano G, Cioffi A, Guardasole V, Angelini V, Guidetti G, Barbera S, Renda F, Romano F, Volpintesta A, Robbiati SF, Sannicolò M, Filipazzi V, Esani G, Gambaro A, Ferrario S, Tinessa V, Caprio MG, Zonato S, Cabiddu M, Raina A, Veltri E, D'Aprile M, Pistillucci G, Porcile G, Ostellino O, Vinante O, Azzarello G, Gebbia V, Borsellino N, Testa A, Gasparini G, Morabito A, Gattuso D, Romito S, Carrozza F, Fava S, Calcagno A, Grimi E, Bertetto O, Ciuffreda L, Parello G, Maiorino L, Santoro A, Santoro M, Failla G, Aiello RA, Bearz A, Sorio R, Scalone S, Clerici M, Bollina R, Belloni P, Sacco C, Sibau A, Adamo V, Altavilla G, Scimone A, Spatafora M, Bellia V, Hopps MR, Monfardini S, Favaretto A, Stefani M, Corradini GM, Pavia G, Scagliotti G, Novello S, Selvaggi G, Tonato M, Darwish S, Michetti G, Belometti MO, Labianca R, Quadri A, De Marinis F, Migliorino MR, Martelli O, Colucci G, Galetta D, Giotta F, Isa L, Candido P, Rossi N, Calandriello A, Ferrà F, Malaponte E, Barni S, Cazzaniga M, Gebbia N, Valerio MR, Belli M, Colantuoni G, Capuano MA, Angiolillo M, Sollitto F, Ardizzoia A, Luporini G, Locatelli MC, Pari F, Aitini E, Pedicini T, Febbraro A, Zollo C, Di Costanzo F, Bartolucci R, Gasperoni S, Gaion F, Palazzolo G, Galligioni E, Caffo O, Cortesi E, D'Auria G, Curcio C, Vasta M, Bumma C, Celano A, Bretti S, Nettis G, Anselmo A, Mattioli R, Nisticò C, Aschelter A, Foa P. Supportive care in patients with advanced non-small-cell lung cancer.

Br J Cancer. 2003 Sep 15;89(6):1013-21.

Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.).

Anticancer Res. 2003 Sep-Oct;23(5b):4219-22.

Gebbia V, Di Marco P, Borsellino N, Gebbia N, Valerio MR, Fallica G, Tirrito ML, Valenza R, Citarrella P, Benedetti Panici P. Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.

Anticancer Drugs. 2003 Jun;14(5):359-64.

Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G; Gruppo Oncologico Italia Meridionale. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.

Lung Cancer. 2003 Feb;39(2):179-89.

Bazan V, Migliavacca M, Zanna I, Tubiolo C, Corsale S, Calò V, Amato A, Cammareri P, Latteri F, Grassi N, Fulfaro F, Porcasi R, Morello V, Nuara RB, Dardanoni G, Salerno S, Valerio MR, Dusonchet L, Gerbino A, Gebbia N, Tomasino RM, Russo A. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.

J Cancer Res Clin Oncol. 2002 Dec;128(12):650-8.

Russo A, Migliavacca M, Zanna I, Valerio MR, Latteri MA, Grassi N, Pantuso G, Salerno S, Dardanoni G, Albanese I, La Farina M, Tomasino RM, Gebbia N, Bazan V. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1322-31.

Naglieri E, Lopez M, Lelli G, Morelli F, Amodio A, Di Tonno P, Gebbia N, DiSeri M, Chetri MC, Rizzo P, Abbate I, Casamassima A, Selvaggi FP, Colucci G. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.

Anticancer Res. 2002 Sep-Oct;22(5):3045-51.

Bazan V, Zanna I, Migliavacca M, Sanz-Casla MT, Maestro ML, Corsale S, Macaluso M, Dardanoni G, Restivo S, Quintela PL, Bernaldez R, Salerno S, Morello V, Tomasino RM, Gebbia N, Russo A. Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma.

J Cell Physiol. 2002 Sep;192(3):286-93.

Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.

Ann Oncol. 2002 Sep;13(9):1438-46.

Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N, Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G; Gruppo Oncologico Italia Meridionale. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C instage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Lung Cancer. 2002 Aug;37(2):179-87.

Vici P, Colucci G, Gebbia V, Amodio A, Giotta F, Belli F, Conti F, Gebbia N, Pezzella G, Valerio MR, Brandi M, Pisconti S, Durini E, Giannarelli D, Lopez M. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.
J Clin Oncol. 2002 Jun 1;20(11):2689-94.

Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Amato A, Calò V, Dardanoni G, Morello V, La Farina M, Albanese I, Tomasino RM, Gebbia N, Russo A. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
J Cell Physiol. 2002 May;191(2):237-46.

Russo A, Zanna I, Tubiolo C, Migliavacca M, Bazan V, Latteri MA, Tomasino RM, Gebbia N. Hereditary common cancers: molecular and clinical genetics.
Anticancer Res. 2000 Nov-Dec;20(6C):4841-51.

Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Cigolari S, Fortunato S, Pedicini T, Borsellino N, Lopez M, Colucci G. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Ann Oncol. 2000 Aug;11(8):1045-51.

Gebbia N, Martello A, Bajardi E. [Preclinic of the new molecules active on colorectal neoplasms].
Tumori. 2000 May-Jun;86(3 Suppl):S9-14. .

Russo A, Bazan V, Migliavacca M, Zanna I, Tubiolo C, Tumminello FM, Dardanoni G, Cajozzo M, Bazan P, Modica G, Latteri M, Tomasino RM, Colucci G, Gebbia N, Leto G. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma.
Clin Cancer Res. 2000 Jan;6(1):178-84.

Colucci G, Giuliani F, Gebbia V, Testa A, Borsellino N, Lelli G, Fortunato S, Lopez M, Maiello E, Gebbia N. Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM).
Am J Clin Oncol. 1999 Jun;22(3):262-6.

Maiello E, Gebbia V, Giuliani F, Testa A, Giotta F, Gebbia N, Colucci G. A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma.
Clin Ter. 1998 Sep-Oct;149(5):351-5.

Palmeri S, Meli M, Danova M, Bernardo G, Leonardi V, Dastoli G, Rausa L, Russo A, Filippelli G, Palmieri G, Russo A, Della Vittoria Scarpati M, Lo Russo V, Di Lauro L, Colucci G, Bruni G, Piazzi M, Gebbia N, Spada S. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
J Cancer Res Clin Oncol. 1998;124(3-4):191-8.

Gebbia V, Borsellino N, Testa A, Latteri MA, Milia V, Valdesi M, Giotta F, Gebbia N, Colucci G. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). *Anticancer Drugs*. 1997 Nov;8(10):943-8.

Gebbia V, Mantovani G, Farris A, Agostara B, Desogus A, Curreli L, Moschella F, Di Gregorio C, Bajetta E, Gebbia N. Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study. *Cancer*. 1997 Apr 1;79(7):1394-400.

Colucci G, Giotta F, Gebbia V, Riccardi F, Pezzella G, Durini E, Caruso M, Romito S, Gebbia N. Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group. *Anticancer Drugs*. 1997 Mar;8(3):257-64.

Colucci G, Gebbia V, Galetta D, Riccardi F, Cariello S, Gebbia N. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM). *Br J Cancer*. 1997;76(11):1509-17.

Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Gebbia N. Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. *Oncology*. 1997 Jan-Feb;54(1):79-83.

Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Carroccio A, Ippolito S, Gebbia N. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. *Pancreas*. 1997 Jan;14(1):22-7.

Gebbia V, Majello E, Testa A, Pezzella G, Giuseppe S, Giotta F, Riccardi F, Fortunato S, Colucci G, Gebbia N. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). *Cancer*. 1996 Sep 15;78(6):1300-7.

Gebbia V, Testa A, Cannata G, Gebbia N. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. *Anticancer Drugs*. 1996 Sep;7(7):734-7.

Maiello E, Giotta F, Gebbia V, Testa A, Galetta D, Riccardi F, Gebbia N, Colucci G. Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients. *Anticancer Res*. 1996 Sep-Oct;16(5B):3177-9.

Gebbia N, Gebbia V. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. *Eur J Cancer*. 1996 Sep;32A(10):1822-3.

Tumminello FM, Leto G, Pizzolanti G, Candiloro V, Crescimanno M, Crosta L, Flandina C, Montalto G, Soresi M, Carroccio A, Bascone F, Ruggeri I, Ippolito S, Gebbia N. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. *Anticancer Res* 1996 Nov-Dec;16(6C):4003.

Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Ruggeri I, Gebbia N. Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. *Eur J Clin Chem Clin Biochem*. 1996 Jul;34(7):555-60.

Colucci G, Maiello E, Gebbia V, Cifarelli RA, Biglietto M, Pedicini A, Durini E, Giuliani F, Gebbia N. Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma: a multicentric phase II study of the Southern Italy Oncology Group (GOIM). *Oncology*. 1996 Jul-Aug;53(4):269-74.

Gebbia V, Galetta D, Majello E, Valenza R, Colucci G, Gebbia N. Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). *Am J Clin Oncol*. 1996 Jun;19(3):278-80.

Gebbia V, Testa A, Majello E, Cannata G, Tirrito ML, Mastrandrea G, Feo M, Bajardi G, Colucci G, Gebbia N. Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma. *Anticancer Drugs*. 1996 Jun;7(4):386-91.

Gebbia V, Testa A, Gebbia N. Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. *Br J Cancer*. 1996 Jun;73(12):1576-80.

Gebbia V, Testa A, Cannata G, Gebbia N. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. *Eur J Cancer*. 1996 May;32A(5):901-2. .

Gebbia V, Testa A, Valenza R, Cannata G, Tirrito ML, Gebbia N. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. *Cancer*. 1995 Nov 15;76(10):1821-8.

Russo A, Bazan V, Gebbia N, Pizzolanti G, Tumminello FM, Dardanoni G, Ingoia F, Restivo S, Tomasino RM, Leto G. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance. *Cancer*. 1995 Nov 15;76(10):1757-64.

Gebbia V, Testa A, Di Gregorio C, Ingria F, Valenza R, Cannata G, Moschella F, Restivo G, Gebbia N. Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. *Am J Clin Oncol*. 1995 Aug;18(4):293-6.

Latteri MA, Cipolla C, Gebbia V, Lampasona G, Amato C, Gebbia N. Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases. *Eur J Surg Oncol*. 1995 Aug;21(4):432-4.

Tumminello FM, Gebbia N, Pizzolanti G, Russo A, Bazan V, Leto G. Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: a preliminary report. *Oncology*. 1995 May-Jun;52(3):237-42.

Gebbia V, Valenza R, Testa A, Cipolla C, Latteri M, Curto G, Comande S, Buccellato C, Gebbia N. Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. *Am J Clin Oncol*. 1994 Dec;17(6):485-9.

Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, Latteri MA, Gebbia N. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. *Cancer*. 1994 Oct 1;74(7):1945-52.

Gebbia V, Valenza R, Testa A, Borsellino N, Cannata G, Restivo S, Speciale R, Ingria F, Spadafora G, Gebbia N. Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck. *ORL J Otorhinolaryngol Relat Spec*. 1994 Sep-Oct;56(5):279-82.

Gebbia N, Mannino R, Di Dino A, Maxhouni L, Bellone N, Cinque L, Liuzza A, LaMotta P, Cannata G, Gulotta G, et al. Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. *Anticancer Res*. 1994 Mar-Apr;14(2B):739-45. Review.

Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N. A prospective randomized trial of thymopentin versus granulocyte-colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. *Anticancer Res*. 1994 Mar-Apr;14(2B):731-4.

Leto G, Pizzolanti G, Tumminello FM, Gebbia N. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors. *In Vivo*. 1994 Mar-Apr;8(2):231-6.

Agostara B, Gebbia V, Testa A, Cusimano MP, Gebbia N, Callari AM. Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. *Tumori*. 1994 Feb 28;80(1):33-6.

Callari A, Gebbia V, Testa A, Cusimano MP, Cipolla C, Amato C, Cannata G, Latteri MA, Garascia C, Gebbia N, et al. A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. *Acta Oncol*. 1994;33(8):925-9.

Gebbia V, Testa A, Valenza R, Cannata G, Verderame F, Gebbia N. Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity. *Eur J Cancer*. 1994;30A(6):889. .

Gebbia V, Valenza R, Testa A, Cannata G, Verderame F, Gebbia N. Escalating doses of mitoxantrone with granulocyte colony-stimulating factor(G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. *Eur J Cancer*. 1994;30A(11):1734-6. .

Gebbia V, Testa A, Borsellino N, Cannata G, Valenza R, Gebbia N. Pharmacological modulation of 5-fluorouracil and its clinical implications: an overview. *In Vivo*. 1993 Nov-Dec;7(6B):639-44. Review.

Gebbia V, Testa A, Valenza R, Borsellino N, Cipolla C, Cannata G, Curto G, Latteri M, Florena M, Gebbia N. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. *J Chemother*. 1993 Jun;5(3):186-90.

Tumminello FM, Bernacki RJ, Gebbia N, Leto G. Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications. *Med Res Rev*. 1993 Mar;13(2):199-208. .

Gebbia V, Testa A, Valenza R, Cipolla C, Amato C, Latteri M, Gebbia N, Florena M. Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma. *Anticancer Res*. 1993 Jan-Feb;13(1):141-4.

Russo A, Gebbia V, Palmeri S, Geraci P, Maneschi F, Guarnieri G, Carollo F, Leonardi V, Meli M, Gebbia N, et al. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma. *Eur J Gynaecol Oncol*. 1993;14(3):228-33.

Gebbia V, Testa A, Valenza R, Zerillo G, Restivo S, Ingria F, Cannata G, Gebbia N. A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. *Eur J Cancer*. 1993;29A(9):1358-9. .

Gebbia V, Gebbia N, Russo A, Testa A, Valenza R, Zerillo G, Ingria F, Spadafora G, Rausa L. Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy. *Anticancer Drugs*. 1992 Aug;3(4):347-9.

Gebbia V, Russo A, Gebbia N, Rausa L, Ingria F, Spatafora G, Zerillo G, Cimino A, Pastorello T, Ferrara P, et al. High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck. *J Cancer Res Clin Oncol*. 1992;118(6):458-62.

Palmeri S, Gebbia V, Russo A, Gebbia N, Rustum Y, Rausa L. Cisplatin in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma. *Cancer Invest*. 1992;10(6):497-504.

Gebbia V, Zerillo G, Gebbia N, Agostara B, Callari A, Rausa L. Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease.
J Chemother. 1992 Aug;4(4):244-59.

Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D in the malignant progression of neoplastic diseases (review).
Anticancer Res. 1992 Jan-Feb;12(1):235-40. Review.

Buscemi M, Gerbino A, Tessitore V, Leto G, Tumminello FM, Gebbia N, Rausa L. Nephrotoxic effects of pepstatin A. An histoenzymologic study.
Pharmacol Res. 1990 Sep-Oct;22 Suppl 1:59-60. .

Gebbia V, Gebbia N, Rausa L, Sharkis SJ, May WS. In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1.
Pharmacol Res. 1990 Sep-Oct;22 Suppl 1:103-4. .

Leto G, Tumminello FM, Gebbia N, Woynarowska B, Bernacki RJ. Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice.
Anticancer Res. 1990 Jan-Feb;10(1):265-9.

Tumminello FM, Leto G, Gebbia N, Rausa L, Bernacki RJ. Evaluation of antitumor and antimetastatic activity of pepstatin A in some experimental tumor models.
J Chemother. 1989 Jul;1(4 Suppl):1135-8. .

Leto G, Tumminello FM, Gebbia N, Rausa L. Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A.
Int J Biochem. 1988;20(9):917-20.

Gebbia N, Flandina C, Leto G, Tumminello FM, Sanguedolce R, Candiloro V, Gagliano M, Rausa L. The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse.
Tumori. 1987 Jun 30;73(3):279-87.

Gebbia N, Leto G, Gagliano M, Tumminello FM, Rausa L. Lysosomal alterations in heart and liver of mice treated with doxorubicin.
Cancer Chemother Pharmacol. 1985;15(1):26-30.

D'Alessandro N, Gebbia N, Crescimanno M, Flandina C, Leto G, Tumminello FM, Messina L. Effects of amsacrine (m-AMSA), a new aminoacridine antitumor drug, on the rabbit heart.
Cancer Treat Rep. 1983 May;67(5):467-74.

D'Alessandro N, Gebbia N, Biondo F, Campio L, Leto G, Tumminello F, Rausa L. Haemopoietic effects of 7 alpha, 17 beta dimethyltestosterone.
Pharmacol Res Commun. 1979 Feb;11(2):81-94. .

Pavone-Macaluso M, Gebbia N, Biondo F, Bertolini S, Caramia G, Rizzo FP. Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits.
Urol Res. 1976 Apr 21;4(1):9-13.

Pavone-Macaluso M, Gebbia N. Absorption of drugs from the bladder and intravesical chemotherapy.
Urol Res. 1976 Apr 21;4(1):1-3. .

Pavone-Macaluso M, Rizzo FP, Caramia G, Ascoli R, Gebbia N, Biondo F, Mazzarese S, Butera G. [Absorption of drugs through the bladder. Experiences with antineoplastic agents] *Recenti Prog Med.* 1975 Nov;59(5):479-96. .

Pavone-Macaluso M, Rausa L, Gebbia N, Caramia G, Rizzo FP, Arena E, Tessitore V, Vecchioni M. Clinical and experimental projects on chemotherapy of bladder tumours. *S Afr Med J.* 1974 Mar 30;48(15):631-6. .

Pavone-Macaluso M, Gebbia N, Biondo F, Rizzo FP, Caramia G, Rausa L. Experimental techniques for testing the sensitivity of bladder tumours to antineoplastic drugs. *Urol Res.* 1973 May;1(2):60-6. .

Arena A, D'Alessandro N, Dusonchet L, Gebbia N, Gerbasi F, Rausa L, Sanguedolce R. [Analysis of some factors responsible for the bactericidal action and resistance to streptomycin of the *E. coli* cells] *G Ital Chemioter.* 1973 Jan-Dec;20(1-4):46-51.

Arena E, D'Alessandro N, Dusonchet L, Gebbia N, Gerbasi F, Palazzoadriano M, Raineri A, Rausa L, Tubaro E. Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity. *Arzneimittelforschung.* 1971 Aug;21(8):1258-63. .

Arena E, Dusonchet L, Gebbia N, Gerbasi F, Guardo M. [Passage of AMP through the membrane of *E. coli* K 12 in the presence of antibacterial drugs] *Antibiotica.* 1968 Dec;6(4):336-45. .

Arena E, Dusonchet L, Gebbia N, Giammanco G, Guardo M, Rausa L. Changes of the intracellular water space produced by antibacterial drugs in relation to membrane permeability and membrane lesions. *Br J Pharmacol.* 1968 Nov;34(3):671P-672P. .

Rausa L, Arena E, Gebbia N, Guardo M. On the possible causes of the release of material absorbing at 260 m- μ by streptomycin treated *E. coli* cells (K 12 and B). *J Antibiot (Tokyo).* 1967 Jul;20(3):142-8. .

Rausa L, Cannizzaro G, Arena E, Gebbia N. [Release of nucleotides and integrity of the bacterial membrane (*E. coli* K 12)] *Antibiotica.* 1966 Dec;4(4):283-97.

Rausa L, Cannizzaro G, Arena E, Gebbia N. [Analysis of the factors regulating the penetration of Na² S₃₅ O₄ in *E. coli*] *Boll Soc Ital Biol Sper.* 1965 Mar 31;41(6):297-9.